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The growth/motility factor hepatocyte growth factor/scatter factor (HGF/SF) and its receptor, the tyrosine
kinase MET, constitute a signalling system essential for embryogenesis and for tissue/organ regeneration in
post-natal life. HGF/SF-MET signalling, however, also plays a key role in the onset of metastasis of a large
number of human tumours. Both HGF/SF and MET are high molecular weight proteins that bury an
extensive interface upon complex formation and thus constitute a challenging target for the
development of low molecular weight inhibitors. Here we have used surface plasmon resonance (SPR),
nuclear magnetic resonance (NMR) and X-ray crystallography to screen a diverse fragment library of
1338 members as well as a range of piperazine-like compounds. Several small molecules were found to
bind in the lysine-binding pocket of the kringle 1 domain of HGF/SF and its truncated splice variant NK1.
We have deﬁned the binding mode of these compounds, explored their biological activity and we show
that selected fragments inhibit MET downstream signalling. Thus we demonstrate that targeting the
lysine-binding pocket of NK1 is an eﬀective strategy to generate MET receptor antagonists and we oﬀer
proof of concept that the HGF/SF-MET interface may be successfully targeted with small molecules.
These studies have broad implications for the development of HGF/SF-MET therapeutics and cancer
treatment.Introduction
Hepatocyte growth factor/scatter factor (HGF/SF)1,2 is a growth
and motility factor essential for embryogenesis,3,4 liver regen-
eration5,6 and the repair of skin wounds.7 Binding of HGF/SF to
its receptor, the MET tyrosine kinase,8 activates several signal-
ling pathways including Ras/MAPK, PI3K/Akt and JAK/STAT.9,10
HGF/SF and MET also play crucial roles in human cancer where
they control survival, growth and migration of tumour cellsof Cambridge, 80 Tennis Court Road,
m.ac.uk; sigurdar@mrc-lmb.cam.ac.uk
ills Road, Cambridge, CB2 0QH, UK
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Pavia, Italy
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sc02155c
olecular Biology, Francis Crick Avenue,
Department of Biochemistry, Lancaster
hemistry 2015leading to metastasis.9,10 Abnormal MET signalling in human
cancer is due to activating mutations11 or, more frequently, to
over-expression of either ligand or receptor.12,13
HGF/SF has a domain structure and proteolytic mechanism
of activation similar to those of the blood proteinase precursor
plasminogen.14 The inactive precursor form of HGF/SF is
cleaved at a trypsin-like site located between the fourth kringle
(K) and the C-terminal domain. Cleavage produces an active,
disulphide-linked, two-chain protein15 consisting of a 69 kDa a-
chain and a 34 kDa b-chain which is homologous to the catalytic
domains of serine proteinases (SPH domain) (Fig. 1a).14 Two
truncated forms of HGF/SF are produced by alternative splicing
of the primary transcript: NK1 encodes the N domain and the
rst K domain (K1),16 while NK2 encodes the N, K1 and K2
domains.17 Both NK1 and NK2 were initially described as
receptor antagonists, but experiments in transgenic mice have
demonstrated unequivocally that NK1 behaves in vivo as a
partial receptor agonist.18 NK1 is a monomer in solution, but
crystallises as a head-to-tail dimer (Fig. 1b) and all available
crystal structures of human and mouse NK1 yielded the same
dimer.19–22
The key role of HGF/SF-MET signalling in metastasis has
propelled MET among the top targets for human cancerChem. Sci., 2015, 6, 6147–6157 | 6147
Fig. 1 HGF/SF and its NK1 splice variant. (a) Domain structure of HGF/
SF. The N-domain and the ﬁrst kringle domain form NK1, a receptor
agonist. Domains N with K1 to K4 form the a-chain of mature, acti-
vated HGF/SF. The a-chain is covalently linked to the b-chain, which
consists of a serine-proteinase homology domain (SPH). (b) Crystal
structure of the NK1 head-to-tail dimer (PDB accession: 1BHT21).
Protomers are labelled A (green) and B (cyan), the N- and K-domains
are indicated and the lysine-binding pocket is encircled. (c) The lysine-
binding pocket of the kringle domain of NK1 is formed by a glycine
loop at the top of pocket (E183 and G186), an aromatic “base” (W188)
and sides (F162 and Y198), as well as a positively charged anchor at the
bottom of the pocket (R197). Main-chain segments are shown in cyan,
side chain carbon atoms are in light gray, oxygen atoms are in red and
nitrogen atoms in blue. A HEPES molecule is bound in the pocket and
shown with its carbon atoms in dark gray and its sulphur atom in
yellow. Hydrogen bonds between the HEPES molecule and NK1 are
represented by dashed lines. (In relationship to (b), (c) is rotated 180
around the x-axis.)
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View Article Onlinetherapy23 and substantial progress has been made in recent
years in developing inhibitors of the MET kinase and antibodies
directed to HGF/SF or the MET ectodomain. However, there are
potential limitations to both approaches. Resistance to kinase
inhibitors develops rapidly through mutations24 and antibodies
– which may not be hampered by the development of resistance
– may prove prohibitively expensive for the large cancer patient
groups in which MET is involved.
Here we propose and explore a novel strategy toward MET
therapeutics, namely small molecule receptor antagonists.
These molecules, may potentially overcome the limitations of
the kinase inhibitors and antibodies, and may have a further
advantage over kinase inhibitors, namely the fact that their site
of action is extracellular.
HGF/SF binds the N-terminal b-propeller domain of MET,
utilising two binding sites: a high-aﬃnity site located within the
NK1 fragment and a low-aﬃnity one contained within the SPH
domain.25–28 Mutagenesis studies identied several residues
clustered in solvent exposed areas of the K domain of NK1
(E159, S161, E195, R197 and Y198) which are involved in
receptor binding or activation28 (Fig. 1b). This patch of residues
is surrounded by a pocket,19,21 similar to the one shown to bind
lysine in the K domains of other proteins.29,30 Three of seven6148 | Chem. Sci., 2015, 6, 6147–6157residues that contribute to the binding pocket in the K4 domain
of plasminogen are not conserved in the one present in the K1
domain of HGF/SF, and a glycine residue (G185) is inserted in
the loop that borders one side of pocket, resulting in a
substantial change in conformation. These diﬀerences may not
enable binding of lysine side chains or lysine analogues but we
retain the name ‘lysine-binding pocket’ throughout the present
work in order to acknowledge the structural homology.
A HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid) molecule was found bound into this pocket in several
crystal structures of NK1 (ref. 20–22) suggesting aﬃnity for
sulphated molecules in vivo. We hypothesised that the lysine-
binding pocket of K1 of HGF/SF could oﬀer a way to target the
HGF/SF-MET interface and undertook a fragment screen in
order to test this hypothesis. Here we report that several small
molecules bind into this pocket and can inhibit MET signalling.
Thus we provide proof of concept for a new class of MET
inhibitors for cancer therapy, namely small-molecule receptor
antagonists.
Results
Piperazine-like compounds bind into the lysine-binding
pocket of HGF/SF
Several crystal structures of NK1, for example 1BHT,21 1GMN20
and 1GP9,22 have shown a HEPES molecule bound in the lysine-
binding pocket of the K1 domain. It has also been observed that
the formation of NK1-MET complexes was inhibited in buﬀers
containing 50 mM HEPES (Lauris Kemp, personal communi-
cation). The pocket is elliptical in shape with a total volume of
211 A˚3. It is made up of a largely aromatic “base” (W188),
aromatic pocket sides (F162 and Y198), an entrance bracketed
by a positively charged surface at one end (R181 and R197) and a
neutral glycine loop involving G185 and G186 at the opposite
end (Fig. 1b and c). These features make the pocket quite
complex in nature and attractive from the point of view of drug
development.
In initial experiments HEPES was successfully incorporated
into apo NK1 crystals by soaking and bound into the lysine-
binding pocket in a mode consistent with previous results.
Next, three classes of piperazine-like sulphonated compounds
containing piperazine ((H)EPPS and PIPES), morpholine (MES
andMOPS), or cyclohexane (CHES and CAPS) rings were studied
for their binding to NK1 (Table 1), alongside another ve sul-
phonated compounds selected from a chemical fragment
library (Table 2). All compounds were soaked into NK1 apo
crystals that diﬀracted to maximum resolutions ranging from
1.9 to 2.5 A˚; the space group was determined to be P21 in all
cases, with unit cell parameters comparable to those of the apo
crystals. For crystallographic statistics, see ESI Tables S1 and
S2.† Fig. S1† shows representative examples of the electron
density of the lysine-binding pocket for NK1 in complex with the
piperazine-like compounds.
All piperazine-like molecules bound into the lysine-binding
pocket of NK1 (Fig. 2) and an overlay of the three classes of
piperazine-like sulphonated compounds bound to NK1 is
shown in ESI Fig. S2.†HEPES forms two crucial hydrogen bondsThis journal is © The Royal Society of Chemistry 2015
Table 1 Compounds selected for soaking into NK1 apo crystals. Piperazine-like compounds with a sulphonic acid group and their binding
constants obtained using SPR and NMR
Piperazine-like compounds Structure KD in SPR
a [mM] KD in NMR
a [mM]
HEPES 2.4  0.4 3.3  0.4
(H)EPPS 7.0  1.0 4.4  1.8
PIPES 26.6  0.6 45.9  4.7
MES 24.3  3.1 13.4  5.7
MOPS 7.0  1.0 4.7  1.7
CHES 30.2  3.1 15.7  4.5
CAPS 1.2  0.2 1.4  0.5
a Steady-state binding constants.
Table 2 Compounds selected for soaking into NK1 apo crystals. Small
compounds that have a sulphonic acid group
Compound name Structure
Taurine
3-Hydroxypropane-1-sulphonic acid (2FA)
p-Toluene sulphonic acid
Propargyl benzene sulphonate
3-Amino-1-propane sulphonic acid
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View Article Onlineto R197 through the sulphonic acid group (distance 2.7–2.8 A˚)
and one main chain hydrogen bond to S161 through a water
molecule. The piperazine moiety of HEPES makes strong
carbon and donor p-interactions with W188 and Y198, and
weak polar interactions with E183, whereas the hydroxyl groupThis journal is © The Royal Society of Chemistry 2015engages the glycine loop in weak polar interactions (Fig. 2a).
While the binding mode of (H)EPPS is very similar to that of
HEPES, the propane sulphonic acid group rotates and positions
the piperazine ring closer to the entrance of the pocket,
imperfectly stacked against Y198. The compound is unable to
make a hydrogen bond to G186 via its hydroxyl group, but
instead forms a hydrophobic interaction with V200 (Fig. 2b).
PIPES contains ethane sulphonic acid groups on either side of
the piperazine moiety, one of which makes the conserved
hydrogen bonds to R197 while the other forms a hydrogen bond
to G186 and interacts further with the glycine loop through a
water molecule. The length of the compound causes an orien-
tation of the sulphonic acid group towards R197 which is
slightly diﬀerent from the ones observed with HEPES and (H)
EPPS: the piperazine moiety is positioned deeper into the cavity
and the weaker electron density of the compound around G186
suggests a degree of exibility.
MES, MOPS, CHES and CAPS bind the lysine-binding pocket of
NK1 in the same way as HEPES, with their sulphonic groups
forming two hydrogen bonds to R197 and one to S161 mediated
by a water molecule (except CHES) (Fig. 2d–g). However, unlike
HEPES, MES does not occupy the pocket around the glycine
loop, allowing an ethylene glycol molecule to occupy the space
and form a hydrogen bond to G186 (Fig. 2d). CAPS and CHESChem. Sci., 2015, 6, 6147–6157 | 6149
Fig. 2 The piperazine-like compounds bind in the lysine-binding pocket of the kringle domain of NK1. (a) HEPES (cyan, PDB ID: 5COE), (b) (H)
EPPS (green, PDB ID: 5CS3), (c) PIPES (yellow, PDB ID: 5CS5), (d) MES (magenta, PDB ID: 5CS9) (and an ethylene glycol molecule (purple)), (e)
MOPS (orange, PDB ID: 5CSQ), (f) CHES (blue green, PDB ID: 5CT1), (g) CAPS (light blue, PDB ID: 5CT2) and (h) 2FA (cyan, PDB ID: 5CT3), bound in
the lysine-binding pocket of NK1 (light gray). Side chain atoms of residues and water molecules (dark red) involved in binding the compounds are
shown. Hydrogen bonds are represented by red dashed lines, polar interactions by blue dashed lines, hydrophobic interactions by black dashed
lines and p-interactions by green dashed lines. Weak interactions are shown in a lighter colour and stronger interactions by a darker colour.
Protein carbon atoms are gray, oxygen atoms are in red and nitrogen atoms are in blue.
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View Article Onlinecontain an additional nitrogen atom in the sulphonic acid
chain, extending this part of the molecule. CAPS has the longest
chain of all the piperazine-like compounds, which positions the
cyclohexane ring further away from R197 (Fig. 2g). This longer
chain enables CAPS to interact with a larger surface area of the
pocket, including E183 and V200 through hydrophobic inter-
actions. MOPS is a propane sulphonic acid compound like (H)
EPPS and its morpholine group is positioned in a similar
position to the piperazine group of (H)EPPS (Fig. 2e). The
overlaid structures of MOPS and (H)EPPS align well. The extra
carbon in the chain of MOPS allows more p-interactions to
W188 compared to MES and in addition the morpholine ring is
able to interact with the carbonyl oxygen of G186 through a
water molecule.
NK1 crystals soaked with the sulphonated compounds
(Table 2) diﬀracted to a maximum resolution ranging from 1.9
to 2.4 A˚ and the space group was determined to be P21 in all
cases, with unit cell parameters comparable to those previously
collected for apo NK1 crystals. Only one compound however, 3-
hydroxypropane-1-sulphonic acid (2FA, Fig. 2h), was bound in
the lysine-binding pocket (crystallographic statistics are listed in
ESI Tables S1 and S2†). The binding mode for 2FA is similar to
HEPES: the sulphonic acid group forms two hydrogen bonds to
R197 and a hydrogen bond to S161 through a water molecule. In6150 | Chem. Sci., 2015, 6, 6147–6157addition, 2FA makes polar interactions with E183 via its
hydroxyl group and p-interactions with W188 and Y198.
Steady-state binding constants of the seven piperazine-like
compounds were determined using SPR (Fig. 3a and Table 1)
and NMR (Fig. 3b and c and Table 1). In NMR experiments,
chemical shi perturbations of selected residues of the lysine-
binding pocket could be readily observed upon binding of the
compounds. Y198 and G185 showed the largest variations in
chemical shi upon binding, and binding constants were
obtained by titration of the compounds into the protein sample
(representative data with HEPES are shown in Fig. 3b and c, for
other piperazine-like compounds see ESI Fig. S3†). Binding
constants obtained from SPR and NMR are comparable (Table
1) and the gures indicate that CAPS and HEPES display the
highest binding aﬃnities, whereas PIPES and CHES display the
lowest. The aﬃnity data are well rationalised by diﬀerences in
the chain length of the compounds and by the diﬀerent modes
of binding revealed by X-ray crystallography (see Discussion).Screening of a fragment library identies new chemical
entities binding into the lysine-binding pocket of the kringle 1
domain of HGF/SF
A screen of a fragment library of 1338 fragments for NK1
binders was carried out by SPR and yielded 71 conrmed hitsThis journal is © The Royal Society of Chemistry 2015
Fig. 3 Binding aﬃnities of the piperazine-like compounds and MB605 for the lysine-binding pocket of the kringle domain of NK1. (a) Steady-
state binding curves for the piperazine-like compounds from SPR. HEPES (C), (H)EPPS (B), PIPES (;), MES (O), MOPS (,), CHES (-) and CAPS
(A). (b) Binding curves of the residues that experience the largest chemical shift in 2D 1H-15N HSQC NMR spectroscopy upon binding of HEPES
to NK1. S161 (C), R181 (B), E183 (;), E184 (O), G185 (-), W188 (,), R197 (A), Y198 (>) and V200 (:). (c) Overlaid 2D 1H-15N HSQC-spectra of
15N-enriched NK1 in the absence (blue) and presence of 0.9 mM HEPES (red). Selected residues of the lysine-binding binding pocket are
highlighted showing the chemical shift upon binding. (d) Steady-state binding curve of MB605 (C) to immobilized NK1 measured by SPR. (e)
Binding curves of the residues that experience the largest chemical shift upon binding of MB605 to NK1. K144 (|), R181 (B), E183 (;), E184 (O),
G185 (-), W188 (,), R197 (A), E199 (>), V200 (:) and C201 (P). (f) Overlaid 2D 1H-15N HSQC spectra of 15N enriched NK1 in the absence (blue)
and presence (red) of a ligand (MB605 440 mM). Selected residues of the lysine-binding pocket are highlighted showing the chemical shift upon
binding.
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View Article Online(see ESI Materials & Methods and ESI Fig. S4† for full details of
the screen). The 71 compounds could be classied into ve
main scaﬀolds: benzene ring (23), 6-membered heterocyclic
derivatives (12), 5-membered heterocyclic derivatives (22),
bicyclic derivatives (7), and two connected rings (7) (see ESI
Tables S3–S7† for a full list of compounds).
Steady-state binding studies by SPR showed good binding
behaviour and KD < 3 mM for 24 fragments which are deemed
validated hits (ve of which contain a carboxylic acid group). 28
fragments displayed linear, concentration-dependent binding
indicative of stacking on the chip surface and were therefore
discarded. 11 fragments failed to yield reproducible binding.
Ten out of the 24 validated hits had KD < 1 mM (Table 3) with
MB605 being the best fragment hit with a KD value of 310  40
mM (Fig. 3d and Table 3). NMR measurements (1H-15N TROSY-
HSQC) were carried out to assess binding of selected
compounds out of the original 71 hits to NK1. These represent
hits with diﬀerent steady-state aﬃnities: MB605, AT0381 and
MB895 displaying good aﬃnities at <1 mM, MB1299, MB389
and MB915 medium steady-state aﬃnities (1–4.5 mM) and
MB1283 the lowest aﬃnity. Only MB605 showed variation in
chemical shis for several NK1 residues, mainly in and around
the lysine-binding pocket, for example E183, R181 and E184,
yielding a KD of 110 mM  10 mM (Fig. 3e and f) that compares
well with the value obtained by SPR (Fig. 3d and Table 3).
MB605 consists of two parts, a furan and a propanoic
acid moiety, resembling HEPES. A crystal structure of MB605
soaked into NK1 apo crystals (see ESI Tables S1 and S2† forThis journal is © The Royal Society of Chemistry 2015crystallographic statistics) demonstrated a binding mode
similar to HEPES in which the carboxylic acid group of MB605
forms two hydrogen bonds to R197 and one main-chain
hydrogen bond to S161 through a water molecule. In compar-
ison to HEPES, MB605 forms stronger polar interactions and
hydrogen bonds to E183 via the furan ring, as well as additional
polar interactions to R181. The furan ring packs tightly in the
aromatic part of the pocket, stacking against W188 and resting
perpendicular to Y198. In this orientation, MB605 is able to
make p–p interaction to W188 and Y198. Additionally, one
molecule of the cryoprotectant ethylene glycol is bound in the
lysine-binding pocket, 3.5 A˚ away from the furan ring, and makes
hydrogen bonds to G185 and G186 (Fig. 4a), similar to the
NK1_MES structure. An overlay of MB605 and HEPES is shown
in Fig. 4b.
The chemical structures of the nine other fragments with KD
values better than 1 mM (Table 3) resemble MB605 in that they
all contain a ring and a functional group or atoms capable of
forming two hydrogen bonds. While solubility issues prevented
us from obtaining structures of these complexes, we explored
possible binding modes in docking studies using GOLD.31,32 All
compounds successfully docked into the lysine-binding pocket in
a similar position to MB605 and docking scores and interac-
tions were consistent with their experimental KD values (data
not shown). Pharmacophore analysis of the binding of the
fragments and piperazine-like molecules within the lysine-
binding pocket (Fig. 5) highlighted both the pivotal role of
R197 in anchoring the small molecules within the pocketChem. Sci., 2015, 6, 6147–6157 | 6151
Table 3 The ten fragments obtained from fragment screening that showed aﬃnities better than 1 mM: structures, molecular weights, response
levels from the initial fragment screening and respective KD values
Compound name Structure Molecular weight [Da] SPR responsea [%] KD
b [mM]
MB605 140.1 215 0.31  0.04
MB1261 134.1 95 0.35  0.04
MB1318 170.6 61 0.36  0.04
MB1082 146.2 53 0.37  0.04
MB417 180.2 87 0.42  0.04
MB895 157.2 53 0.43  0.05
AT0381 118.1 53 0.74  0.06
CA023 95.1 52 0.77  0.06
MB1284 149.2 90 0.86  0.07
MB1315 162.2 52 0.94  0.09
a Normalised relative value against NK1. b Steady-state binding constant from SPR.
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 3
1 
Ju
ly
 2
01
5.
 D
ow
nl
oa
de
d 
on
 6
/1
8/
20
18
 1
1:
28
:2
2 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinethrough hydrogen bonds and the importance of additional
aromatic interactions made to Y198 and the aromatic base of
the pocket.
We studied ve additional, MB605-related compounds
identied via a substructure search of the ZINC database of
commercially available compounds, namely: (i) 2-thio-
phenepropanoic acid (CAS number 5928-51-8) diﬀering from
MB605 in having a sulphur atom in the 5-membered ring
instead of oxygen, (ii) hydrocinnamic acid (501-520-0) har-
bouring a benzene ring instead of a furan, (iii) 2-phenylethyl
phosphonic acid (4672-30-4), (iv) T5445870, structurally very
similar to MB605 but containing an additional phenyl ring
substituted at the C4 atom of the furan ring and (v) T5480685, a
compound that could stack well against the indole group of
W188 through its benzofuran core. Aﬃnity values for these
compounds were obtained by SPR and range from a KD value of
0.7 to 2.2 mM (Table 4). Compound T5480685 had a KD of 0.7 
0.2 mM and is the best obtained from this set of compounds,
reecting the possible favourable interaction of the benzofuran
to W188. The decrease in aﬃnity for compounds 501-52-0 and6152 | Chem. Sci., 2015, 6, 6147–61574672-30-4 compared to MB605 (and 5928-51-8), demonstrates
that a 5-membered heterocyclic ring is preferred over a benzene
for binding in the aromatic part of the pocket. T5445870 is
structurally very similar to MB605, but the additional phenyl
ring is probably too large to occupy the space by the glycine
loop, which results in a decreased the steady-state aﬃnity of
2.1  0.3 mM.Compounds binding into the lysine-binding pocket of the K1
domain can inhibit NK1-induced MET activation
We evaluated the eﬀect of piperazine-like compounds and
MB605 on Vero cells by assessing MET, Erk 1/2 and Akt phos-
phorylation in response to stimulation using 10 nM NK1.
MB605 was dissolved in DMSO, which limited the range of
concentrations tested to#1mM in order to avoid solvent eﬀects
on cell function/viability. The water-soluble piperazine-like
compounds, in contrast, could be tested at concentrations up
to 100 mM. Inhibition of phosphorylation of Erk 1/2 and Akt
(S473) was seen for HEPES, (H)EPPS, MES, MOPS and CAPSThis journal is © The Royal Society of Chemistry 2015
Fig. 4 Binding of MB605 in the lysine-binding pocket of the kringle
domain of NK1. (a) MB605 (green, PDB ID: 5CP9) binds in the lysine-
binding pocket with a binding mode similar to HEPES but forms
additional hydrogen bonds to R181 and E183 accounting for a higher
aﬃnity. An ethylene glycol molecule (purple) is bound in the
NK1_MB605 structure ﬁlling the top of the pocket. Hydrogen bonds
are represented by red dashed lines, polar interactions by blue dashed
lines, hydrophobic interactions by black dashed lines and p-interac-
tions by green dashed lines. Weak interactions are shown in a lighter
colour and stronger interactions by a darker colour. (b) Comparison of
the binding mode of MB605 (green) and HEPES (cyan). Side chain
atoms of residues and a water molecule (dark red) involved in binding
are shown. Protein carbon atoms are gray, oxygen atoms are in red
and nitrogen atoms are in blue.
Fig. 5 Pharmacophore model of the NK1 lysine-binding pocket,
showing the important interactions made by the piperazine-like and
fragment hits. (a) Key determinants of the shape and the chemical
character of the lysine-binding pocket of the kringle domain of NK1. (b)
The chemical characteristics of the small molecule binders are rep-
resented by mesh spheres, with green representing hydrogen donors
and positive ions, purple aromatic groups, white and orange hydrogen
donors and acceptors respectively, and blue and red positive and
negative ions respectively.
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 3
1 
Ju
ly
 2
01
5.
 D
ow
nl
oa
de
d 
on
 6
/1
8/
20
18
 1
1:
28
:2
2 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online(Fig. 6a–e) at the highest concentration (100 mM, lanes 4).
PIPES and CHES showed similar results (data not shown). CAPS
was also active at a concentration of 10 mM (Fig. 6e, lane 5).
MB605 was tested at three concentrations, ranging from 1
mM to 10 mM (Fig. 6f). The compound was active at a concen-
tration of 1 mM (lane 5), in line with the KD values obtained by
SPR and NMR (Table 3 and Fig. 3).This journal is © The Royal Society of Chemistry 2015Discussion
The lysine-binding pocket of NK1 is important for binding to and
activation of MET, and our results show that compounds
binding into this pocket oﬀer a new way to target the HGF/SF-
MET interface with small molecules. We used three diﬀerent
ways to target this interface: – a fragment screen, which iden-
tied 24 validated hits, – a similarity search based on the best
fragment hit and, – the analysis of a series of molecules related
to a known binder. Binding aﬃnities of the compounds exam-
ined in this study ranged from 0.3 to 30 mM reecting diﬀer-
ences in their structure and their resulting binding. Specically,
we found that aﬃnities increased when:
(I) a hydrogen bond acceptor (carboxylic or sulphonic acid) is
able to anchor the molecule to R197,
(II) a hydroxyl group is able to form a hydrogen bond to
G186,
(III) an alkyl chain or ring structure is present to connect the
acid and hydroxyl group, which is able to t into the aromatic
pocket formed by W188, F162 and Y198 (distance from acid
group to ring is three rather than two carbon atoms) and form
p-interactions (p–p interactions increase the aﬃnity even
further).
All of the compounds discussed here, as conrmed by crys-
tallographic analysis, show the conserved and crucial hydrogen
bonds to R197 and the diﬀerences in binding aﬃnity reect
additional interactions. This is demonstrated, for example, by
HEPES (KD ¼ 2.4 mM) which, compared to (H)EPPS (KD ¼ 7.0
mM) and PIPES (KD ¼ 26.6 mM), forms stronger p-interactions
to W188 an Y198, weak polar interactions to E183 and further
contacts with the glycine loop. Similar arguments explain the
diﬀerence in binding aﬃnity between MOPS (KD¼ 7.0 mM) and
MES (KD¼ 24.3 mM). CAPS (KD¼ 1.2 mM), the longest of all the
piperazine-like compounds, interacts via its cyclohexane ring
with a larger surface of the pocket, including E183 and V200,
making it the highest aﬃnity piperazine-like compound.
MB605 on the other hand has its furan ring in an ideal orien-
tation to form strong p–p interactions with both W188 and
Y198, in addition to making stronger polar interactions and
hydrogen bonds to E183 than any of the piperazine-like
compounds and an additional polar interaction to R181;
yielding the highest aﬃnity reported here (KD ¼ 310 mM).
These promising results clearly set the prospect of a new
class of MET inhibitors targeting the lysine-binding pocket of the
rst kringle domain of HGF/SF, but further work is needed in
order to increase the aﬃnity and hence the potency of the
compounds as well as to ensure target specicity. Kringle
domains are present in a variety of proteins of the brinolytic
and blood coagulation system including plasminogen,33 tissue
plasminogen activator,34 urokinase plasminogen activator,35
and thrombin, as well as in several other proteins such as apo(a)
and the ROR1/2 receptors. Despite the apparently uniform
structural characteristics, the lysine-binding pocket of diﬀerent
kringle domains, are responsible for the binding specicity of
the cognate proteins. For example, the aﬃnity of human plas-
minogen and tissue plasminogen activator for brin appears toChem. Sci., 2015, 6, 6147–6157 | 6153
Table 4 Five compounds obtained based on MB605 substructure similarity: structures, molecular weights and respective KD values
Compound name Structure Molecular weight [Da] KD
a [mM]
5928-51-8 156.2 1.1  0.3
501-520-0 150.2 2.2  0.9
4672-30-4 186.1 2.2  0.4
T5445870 234.2 2.1  0.3
T5480685 190.2 0.7  0.2
a Steady-state binding constant from SPR.
Fig. 6 Biological activity of the piperazine-like compounds and
MB605. (a–e) Vero cells expressing the receptor endogenously on
their cell surface were stimulated with HGF/SF or NK1 and phos-
phorylation of MET and downstream targets Akt and Erk1/2 was ana-
lysed. Piperazine-like compounds HEPES (a), (H)EPPS (b), MES (c),
MOPS (d) and CAPS (e) were tested at 100 mM (lanes 4), 10 mM (lanes
5), 1 mM (lanes 6) and 100 mM (lanes 7) concentration in the presence
of 1 nM NK1. To control for activating or inhibiting eﬀects of the
compounds independently of MET, piperazine-like compounds were
tested on cells at 100 mM without stimulation by NK1 (lanes 3). Bio-
logical activity of MB605 (f) was investigated at 1 mM (lane 5), 100 mM
(lane 6) and 10 mM (lane 7) in the presence of a constant concentration
of DMSO (0.1%). A solvent control (0.1% DMSO, lane 3) was included in
order to account for the eﬀect of DMSO on the cells. A positive control
(1 nM NK1 in the presence of 0.1% DMSO) is shown in lane 4. In all
experiments, un-stimulated cells served as negative control (lanes 1)
while cells stimulated with 1 nM NK1 served as positive control
(lanes 2).
6154 | Chem. Sci., 2015, 6, 6147–6157
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View Article Onlinearise from interactions of selected kringle domains with lysine
side chains exposed by the brin matrix.36 The lysine-binding
pocket of the rst kringle domain of HGF/SF has a distinct
shape and a strong aromatic character, which sets it apart from
the corresponding pockets of the kringle domains of other
proteins.21 Indeed, in spite of clear similarities between the
binding of HEPES to the lysine-binding pocket of the rst kringle
of HGF/SF (Fig. 2a), and the binding of lysine analogues, i.e. the
anti-brinolytic agents 3-aminocaproic acid (EACA) and trans-4-
(aminomethyl)cyclohexane-1-carboxylic acid (AMCHA) to plas-
minogen kringles,37 we have found that neither EACA or
AMCHA binds NK1 (A. G. S., unpublished data). These results
clearly demonstrate that the lysine-binding pockets of the
kringle domains of diﬀerent proteins oﬀer a way to develop
protein-specic inhibitors, a concept rst demonstrated by the
plasminogen-specic EACA and AMCHA and extended here to
MET antagonists.
The fragment-based approach adopted in this study appears
to have considerable potential for targeting protein–protein
interfaces where shallow groves or preformed small, but oen
deep, pockets are present and appear to have a role in the
protein assembly. Protein–protein interfaces typically rely on
shallow protein binding sites, but these oen contain small
well-dened pockets that recognise side chains or chain termini
of proteins or peptides.38,39 This appears to have been true in
work in which the Abbott Laboratories’ targeted Bcl-XL, which
inhibits apoptosis by binding the pro-apoptotic molecule BAK
or another pro-apoptotic molecule BAD. Small molecules that
mimic the alpha-helices involved in these interactions have
been designed by growing from a concave hotspot to give
molecules with aﬃnities of up to 5 nM.40 In our own studies of
the inhibition BRCA2 binding to Rad51, many fragments bindThis journal is © The Royal Society of Chemistry 2015
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View Article Onlineto the phenylalanine-binding pocket of Rad51 and these could
be elaborated into molecules with nanomolar aﬃnities.41
In the present study we have set the foundations for inhibiting
MET signalling using fragments that bind into the lysine-binding
pocket of the K1 domain of HGF/SF. We have identied a new
chemical entity – MB605 – that binds NK1 with sub-millimolar
aﬃnity and displays favourable binding behaviour and activity
in a cellular context. The next step is to grow MB605 into a high-
aﬃnity ligand and the structural and aﬃnity data gained in this
study can clearly guide the development of MB605 and its prog-
ress from hit to lead. MB605 is a very small molecule (140 Da) but
displays about ten times better aﬃnity for NK1 than HEPES and
can be grown towards the glycine loop gaining the chemical
space occupied by the ethylene glycol molecule in the current
crystal structure (Fig. 4a) and enabling hydrogen bonding to the
glycine loop with signicant aﬃnity gain.
Materials and methods
Protein production and purication
NK1 was expressed in methylotrophic P. pastoris and the puri-
cation was carried out in two steps as described previously by
Chirgadze et al.,19 with one modication. MES buﬀer was
removed from the purication process and 50 mM sodium
phosphate, pH 7.4 was used instead. The SPH fragment (Val495-
Ser728) was cloned from cDNA of full length human HGF/SF
into the baculovirus secretion vector pAcGP67A (BD Biosci-
ences) with the addition of a C-terminal hexahistidine tag and a
C604S mutation. Viral stocks were amplied using Sf9 insect
cells (BD Biosciences), and protein was produced using High
Five™ (BTI-TN-5B1-4, Invitrogen) insect cells and ESF 921
(Expression Systems) media (+2.5% FCS). SPH domain was
puried using a 5 mL HP HisTrap (GE Healthcare) column and
a gradient of imidazole from 0–500 mM in 50 mM Tris, pH 7.7.
Protein-containing fractions were pooled, concentrated and
injected onto a 16/60 Superdex 200 prep grade column (Amer-
sham Pharmacia Biotech) equilibrated with 10 mM HEPES, pH
7.2, 150 mM NaCl. Met567 was produced as previously
described in Gherardi et al.42
Piperazine-like compounds
1 M stock solutions of the piperazine-like compounds (Sigma)
were prepared in water and their respective pHs were adjusted
to a value within their buﬀering range by either HCl or NaOH.
The seven piperazine-like compounds and their respective pHs
are: HEPES (pH 7.6), (H)EPPS (pH 7.4), PIPES (pH 7.0), MES (pH
5.8), MOPS (pH 7.2), CHES (pH 8.6) and CAPS (pH 9.7). For the
biological assay the pH of all the piperazine-like compounds
was adjusted to 7.4, in order to match the pH of the media used
to culture the cells in.
Fragment library
The fragment library used in this study is an in-house library
composed of 1338 compounds. Approximately 1200 of the
compounds are from commercial libraries supplied by May-
bridge (Thermo Fisher Scientic: http://www.maybridge.com/).This journal is © The Royal Society of Chemistry 2015In addition to the Maybridge set, the library includes approxi-
mately 100 compounds prepared in the Department of Chem-
istry, University of Cambridge in the laboratory of Prof Chris
Abell, where it is maintained for screening a range of targets. All
compounds are dissolved and stored in 100% DMSO. The
library is not target-tailored. Details of library screening, results
and statistics are given in the ESI† section of the manuscript.
Kinetic measurements using SPR
Binding constants of piperazine-like compounds and fragments
were determined using a Biacore T100 instrument. NK1 was
immobilized on a CM5 chip by amine coupling to a density of
6000 RU. Compounds were stored as 100 mM stock solutions in
water and serial dilutions were prepared in the running buﬀer
(PBS pH 7.4, 0.05% Tween 20). The compound solutions were
injected onto the surface of the chip at a ow rate of 30 mL
min1, contact time was 1 min and dissociation time 1 min.
Sensorgrams were analysed using the Biacore T100 evaluation
soware and the binding constants determined.
Kinetic measurements using NMR
Ligand screening was performed by monitoring the chemical
shi variations in 1H-15N TROSY-HSQC NMR spectra of the
uniformly [15N]-labelled NK1 protein (Fragai et al. 2015, in prep.)
upon the addition of increasing concentrations of the investi-
gated compounds.43–45 The experiments were performed using
0.18 mM protein samples in 25 mM Tris, 100 mM NaCl and
0.01% sodium azide, at pH 7.2 with 10% D2O. The spectra were
recorded at 310 K on a Bruker AVANCE 900 MHz spectrometer
equipped with a TXI cryo-probe. Sample solutions were
prepared from 1 M or 100 mM DMSO stock solutions of the
ligands. The dissociation constant values (KD) were calculated
by plotting the weighted average 1H and 15N chemical shis of
the residues experiencing signicant variations as a function of
ligand concentration added during the titration and consid-
ering the one site binding model.46
NK1 crystallization
NK1 buﬀered in 150 mM NaCl, 50 mM Tris, pH 7.5 (apo-NK1
and all soaking experiments) was concentrated to 20 mg
mL1 using a Vivaspin device with a 10 kDa cut-oﬀ membrane
(Sartorius Biolab). Crystallisation was carried out in Linbro
plates by the vapour diﬀusion hanging drop technique using a
protein : precipitant ratio of 1 : 1 at 20 C. Previously NK1 has
been crystallised in 18% PEG 4000, 200 mM sodium acetate and
150 mM Tris pH 8.5 as precipitant.19 Here nal crystallisation
conditions (19% PEG 4000, 200 mM sodium acetate and 150
mM Tris pH 7.5) were optimised around those to achieve high-
resolution apo structure. Details of compound soaking, X-ray
data collection and structure determination are given in the
ESI† section of the manuscript.
Biological assays
The ability of MB605 and the piperazine-like compounds to
inhibit MET, Erk and Akt phosphorylation in the presence ofChem. Sci., 2015, 6, 6147–6157 | 6155
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View Article OnlineNK1 was tested using mammalian Vero cells as described by
Ferraris et al.47 and further details are given in the ESI† section
of the manuscript.
Conclusions
Although targeting protein–protein interactions using a
fragment-based approach unquestionably remains a major
challenge, the data reported in the present study demonstrate
that a major cancer target such as the HGF/SF-MET interface is
amenable to this approach and provide both the building block
for a small molecule MET antagonist and a roadmap for
developing the MB605 compound into a full therapeutic.
Accession codes
The atomic coordinates and structure factors for the reported
crystal structures have been deposited with the Protein Data
Bank (PDB) under accession code 5CS1 for the NK1 apo struc-
ture and for NK1 complexed with ligands under accession codes
5COE, 5CS3, 5CS5, 5CS9, 5CSQ, 5CT1, 5CT2, 5CT3 and 5CP9.
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